Vaxart reports Q1 net income $5.2M; COVID-19 sentinel data expected Q2 2026

Vaxart, Inc.

2026-Q1 EPS reported $0.02 revenue$39,227,000

Q1 2026 net income $5.2M ($0.02/sh) vs net loss ($15.6M) in Q1 2025.
Revenue $39.2M (+87% YoY) mainly from BARDA contract and Dynavax license.
Cash $61.0M provides runway into Q2 2027; Lincoln Park equity facility up to $25M.
Topline sentinel data from Phase 2b COVID-19 trial (400 participants) anticipated in Q2 2026.
Appointed Dr. James B. Breitmeyer to board; relocated HQ to reduce overhead.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Vaxart, Inc. reported the first quarter of 2026 results: revenue $39.2 million, net income $5.2 million, EPS $0.02.

Period: the first quarter of 2026
Revenue: $39.2 million
Net income: $5.2 million
EPS: $0.02
Result: reported results

Exact text from the filing

funding options, with the goal of achieving its upcoming clinical and regulatory milestones and maximizing stockholder value. ● Revenue for the first quarter of 2026 was $39.2 million, compared to $20.9 million for the first quarter of 2025. Revenue in the first quarter of 2026 and the first quarter of 2025 was primarily from government contracts related to

View on SEC.gov

Browse all earnings releases →

Vaxart, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-015586

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.